Clinical Trial Update: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Web-mediated follow-up kidneyPRO vs standard follow-up in first-line axitinib/pembrolizumab for metastatic renal cell carcinoma remains …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Weprom | Conditions: Renal Cell Carcinoma Metastatic | Phase 3 | Status: UNKNOWN